Patents by Inventor Petr Kuzma

Petr Kuzma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200179480
    Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).
    Type: Application
    Filed: February 18, 2020
    Publication date: June 11, 2020
    Inventor: Petr Kuzma
  • Publication number: 20200046806
    Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.
    Type: Application
    Filed: August 22, 2019
    Publication date: February 13, 2020
    Applicant: Endo Pharmaceuticals Solutions Inc.
    Inventors: Petr Kuzma, Stefanie Decker
  • Publication number: 20190388500
    Abstract: Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent.
    Type: Application
    Filed: September 9, 2019
    Publication date: December 26, 2019
    Applicant: Endo Pharmaceuticals Solutions Inc.
    Inventors: Petr Kuzma, Stephanie Decker
  • Publication number: 20190365847
    Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues car organs.
    Type: Application
    Filed: June 28, 2019
    Publication date: December 5, 2019
    Applicant: Endo Pharmaceuticals Solutions Inc.
    Inventors: Petr Kuzma, Harry Quandt
  • Publication number: 20180280467
    Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).
    Type: Application
    Filed: June 7, 2018
    Publication date: October 4, 2018
    Inventor: Petr Kuzma
  • Publication number: 20170119843
    Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).
    Type: Application
    Filed: January 17, 2017
    Publication date: May 4, 2017
    Inventor: Petr Kuzma
  • Publication number: 20170100461
    Abstract: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a controlled release formulation of octreotide are provided herein.
    Type: Application
    Filed: August 24, 2016
    Publication date: April 13, 2017
    Applicant: ENDO PHARMACEUTICALS SOLUTIONS INC.
    Inventors: Petr Kuzma, Stefanie Decker
  • Publication number: 20170049850
    Abstract: Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent.
    Type: Application
    Filed: August 24, 2016
    Publication date: February 23, 2017
    Applicant: ENDO PHARMACEUTICALS SOLUTIONS INC.
    Inventors: PETR KUZMA, STEFANIE DECKER
  • Publication number: 20160193280
    Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).
    Type: Application
    Filed: November 9, 2015
    Publication date: July 7, 2016
    Applicant: Endo Pharmaceuticals Solutions Inc.
    Inventor: Petr KUZMA
  • Publication number: 20160030337
    Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active risperidone at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of risperidone to tissues or organs.
    Type: Application
    Filed: June 10, 2015
    Publication date: February 4, 2016
    Applicant: BRAEBURN PHARMACEUTICALS BVBA SPRL
    Inventors: Petr Kuzma, Harry Quandt
  • Publication number: 20150283201
    Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues or organs.
    Type: Application
    Filed: November 6, 2014
    Publication date: October 8, 2015
    Applicant: Endo Pharmaceuticals Solutions Inc.
    Inventors: Petr Kuzma, Harry Quandt
  • Patent number: 9120249
    Abstract: Medical implant devices are prepared from a polymeric material and a release agent, where the device is a molded, reservoir implant, and the release agent has a molecular weight (MW) of at least 1000. The release agent may be a non-ionic surfactant such as Brij 35, polyoxyetheylene(20)sorbitan trioleate, Tween 20, Tween 80, vitamin E TPGS, and a mixture of any two or more thereof. Hydrated implants may have a surface area of about 500 mm2 or greater.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: September 1, 2015
    Assignee: ENDO PHARMACEUTICALS SOLUTIONS INC.
    Inventors: Petr Kuzma, Stephanie Decker, Harry Quandt
  • Patent number: 9078900
    Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active risperidone at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of risperidone to tissues or organs.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: July 14, 2015
    Assignee: BRAEBURN PHARMACEUTICALS BVBA SPRL
    Inventors: Petr Kuzma, Harry Quandt
  • Publication number: 20150190413
    Abstract: Compositions and methods for the treatment of bladder cancer include intravesical dosage forms of a neoplastic agent and a permeation enhancer. The neoplastic agent may be valrubicin. Pharmaceutical compositions include intravesical dosage forms of a neoplastic agent complexed liposomes. Tight junction openers may be used for the effective delivery of the neoplastic agent.
    Type: Application
    Filed: March 20, 2015
    Publication date: July 9, 2015
    Applicant: Endo Pharmaceuticals Solutions Inc.
    Inventors: John CHABER, Petr KUZMA, Agis KYDONIEUS
  • Patent number: 9072786
    Abstract: Described herein are implantable devices, formulations and methods of making implantable devices for the release of a polypeptide from an implantable device, and methods of use thereof.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: July 7, 2015
    Assignee: ENDO PHARMACEUTICALS SOLUTIONS INC.
    Inventors: Petr Kuzma, Stefanie Decker, Harry Quandt
  • Publication number: 20150174301
    Abstract: This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises: 1. a reservoir, said reservoir comprising; 2. at least one active ingredient; and, optionally, 3. at least one pharmaceutically acceptable carrier, a polyurethane based polymer completely surrounding the reservoir.
    Type: Application
    Filed: January 30, 2015
    Publication date: June 25, 2015
    Applicant: BRAEBURN PHARMACEUTICAL BVBA SPRL
    Inventors: Sheng-hung KUO, Petr Kuzma
  • Publication number: 20150105746
    Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs.
    Type: Application
    Filed: June 17, 2014
    Publication date: April 16, 2015
    Inventors: Petr Kuzma, Harry Quandt
  • Publication number: 20140349936
    Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).
    Type: Application
    Filed: August 11, 2014
    Publication date: November 27, 2014
    Applicant: Endo Pharmaceuticals Solutions Inc.
    Inventor: Petr KUZMA
  • Patent number: 8784865
    Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: July 22, 2014
    Assignee: Endo Pharmaceuticals Solutions Inc.
    Inventors: Petr Kuzma, Harry Quandt
  • Publication number: 20140135684
    Abstract: This invention is related to the use of polyurethane based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs. The drug delivery device for releasing one or more drugs at controlled rates for an extended period of time to produce local or systemic pharmacological effects comprises: 1. a reservoir, said reservoir comprising; 2. at least one active ingredient; and, optionally, 3. at least one pharmaceutically acceptable carrier; a polyurethane based polymer completely surrounding the reservoir.
    Type: Application
    Filed: January 20, 2014
    Publication date: May 15, 2014
    Applicant: Endo Pharmaceuticals Solutions Inc.
    Inventors: Sheng-hung Kuo, Petr Kuzma